Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michaela Scheurer"'
Autor:
Nora Philipp, Maryam Kazerani, Alyssa Nicholls, Binje Vick, Jan Wulf, Tobias Straub, Michaela Scheurer, Amelie Muth, Gerulf Hänel, Daniel Nixdorf, Monika Sponheimer, Malte Ohlmeyer, Sonja M. Lacher, Bettina Brauchle, Anetta Marcinek, Lisa Rohrbacher, Alexandra Leutbecher, Kai Rejeski, Oliver Weigert, Michael von Bergwelt-Baildon, Sebastian Theurich, Roman Kischel, Irmela Jeremias, Veit Bücklein, Marion Subklewe
Publikováno v:
Blood 140, 1104-1118 (2022)
T-cell–recruiting bispecific molecule therapy has yielded promising results in patients with hematologic malignancies; however, resistance and subsequent relapse remains a major challenge. T-cell exhaustion induced by persistent antigen stimulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c0efbd8fee53c3a987bf6a5a848ae63
https://pubmed.ncbi.nlm.nih.gov/36074532
https://pubmed.ncbi.nlm.nih.gov/36074532
Autor:
Monika Sponheimer, Roman Kischel, Maryam Kazerani Pasikhani, Michael von Bergwelt, Marion Subklewe, Anetta Marcinek, Michaela Scheurer, Daniel Nixdorf, Jan Wulf, Karsten Spiekermann, Alyssa Nicholls, Oliver Weigert, Sonja M Lacher, Alexandra Leutbecher, Gerulf Hänel, Lisa Rohrbacher, Bettina Brauchle, Veit Buecklein, Tobias Straub, Nora Zieger, Sebastian Theurich
Publikováno v:
Blood. 138:513-513
Blinatumomab is a bispecific T-cell engager (BiTE ®) construct approved for treatment of relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). It is applied as continuous infusion over 28 days and induces remissions in 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b247ad098c86aecf3da0b8eb7bba746
https://doi.org/10.1182/blood-2021-150178
https://doi.org/10.1182/blood-2021-150178
Autor:
Karsten Spiekermann, Marion Subklewe, Alyssa Nicholls, Gerulf Hänel, Jan Wulf, Bettina Brauchle, Nora Zieger, Oliver Weigert, Michael von Bergwelt, Sebastian Theurich, Roman Kischel, Daniel Nixdorf, Anetta Marcinek, Veit Buecklein, Lisa Rohrbacher, Maryam Kazerani Pasikhani, Michaela Scheurer
Publikováno v:
Blood. 136:44-45
The bispecific T-cell engager (BiTE®) blinatumomab is approved for treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia and applied as continuous infusion over 28 days. The overall response rate to blinatumomab reported in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3fbb638f7aa32edef30dab342a8d4e5
https://doi.org/10.1182/blood-2020-137421
https://doi.org/10.1182/blood-2020-137421
Autor:
Marion Subklewe, Karsten Spiekermann, Michael von Bergwelt, Roman Kischel, Bettina Brauchle, Michaela Scheurer, Veit Bücklein
Publikováno v:
Blood. 134:2632-2632
Bispecific T-cell engaging (BiTE®) antibody constructs recruit T cells to target antigens independent of their T-cell receptor specificity. Blinatumomab, a CD19xCD3 BiTE® antibody construct, is approved for the treatment of relapsed/refractory (r/r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7a717d3017d5eb0fb6f82af446983d4
https://doi.org/10.1182/blood-2019-129057
https://doi.org/10.1182/blood-2019-129057